Get the Stockscreener App
4.72
4.84%
-0.24
Design Therapeutics Inc stock is traded at $4.72, with a volume of 102.08K.
It is down -4.84% in the last 24 hours and up +18.89% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$4.96
Open:
$4.94
24h Volume:
102.08K
Relative Volume:
0.56
Market Cap:
$267.92M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-3.9333
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
-7.81%
1M Performance:
+18.89%
6M Performance:
-14.80%
1Y Performance:
+76.12%
1-Day Range:
$4.5882
$4.94
1-Week Range:
$4.5882
$5.57
52-Week Range:
$2.4501
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.72 | 267.92M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High? - Nasdaq
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeutics - Yahoo Finance
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Design Therapeutics (DSGN) to Release Earnings on Tuesday - Defense World
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Design Therapeutics provides corporate highlights, anticipated milestones - TipRanks
Design Therapeutics, Inc. SEC 10-K Report - TradingView
Design Therapeutics Initiates Phase 1 Trial for DT-216P2; Reports Progress and Financial Results for 2024 - Nasdaq
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Design Therapeutics Clinical Programs Progress: FA Trial Launches, FECD Dosing Complete - StockTitan
Rhumbline Advisers Increases Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Reasons to Sell DVA and 1 Stock to Buy Instead - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
2 Magnificent Warren Buffett Stocks That Make for Screaming Buys in March, and 1 to Avoid - The Globe and Mail
Design Therapeutics to Participate in Leerink's Global Healthcare Conference - The Manila Times
Clinical-Stage Biotech Design Therapeutics Gears Up for Key Investor Presentation at Leerink Conference - StockTitan
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies - Yahoo Finance
Can Astria's New HAE Drug Data Transform Treatment? Key Findings Revealed at Major Medical Congress - StockTitan
US Penny Stocks To Watch In February 2025 - Simply Wall St
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche - BioSpace
Terrain Biosciences emerges from stealth to enable faster therapeutics and vaccine development with better RNA - Morningstar
AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer - Business Wire
Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study - BioSpace
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in January - MarketBeat
AI-based predictive biology coming soon, Foresite’s Bajaj says - BioCentury
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Increased by JPMorgan Chase & Co. - Defense World
Design Therapeutics: Not A Complete Washout Despite Setback - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - StockTitan
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - Yahoo Finance
Harness going after new target, FAN-1, in Huntington’s disease - BioWorld Online
Assenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Lululemon Athletica Inc. (NASDAQ:LULU) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
THC Therapeutics Has Completed the dHydronator(R) Consumer Model Design - ACCESS Newswire
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - Yahoo Finance
3 Promising US Penny Stocks With Market Caps Under $900M - Simply Wall St
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Significant Increase in Short Interest - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in December - MarketBeat
Barclays PLC Purchases 24,602 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):